Vident Investment Advisory LLC lessened its position in shares of Alkermes Plc (NASDAQ:ALKS) by 46.4% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,868 shares of the company’s stock after selling 4,215 shares during the quarter. Vident Investment Advisory LLC’s holdings in Alkermes were worth $200,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of ALKS. Wells Fargo & Company MN grew its stake in Alkermes by 1.8% during the 1st quarter. Wells Fargo & Company MN now owns 363,014 shares of the company’s stock valued at $21,041,000 after purchasing an additional 6,559 shares during the last quarter. SG Americas Securities LLC grew its stake in Alkermes by 160.4% during the 1st quarter. SG Americas Securities LLC now owns 5,431 shares of the company’s stock valued at $315,000 after purchasing an additional 3,345 shares during the last quarter. Aperio Group LLC grew its stake in Alkermes by 32.9% during the 1st quarter. Aperio Group LLC now owns 35,956 shares of the company’s stock valued at $2,084,000 after purchasing an additional 8,903 shares during the last quarter. Korea Investment CORP purchased a new stake in Alkermes during the 1st quarter valued at about $793,000. Finally, Toronto Dominion Bank grew its stake in Alkermes by 16.2% during the 1st quarter. Toronto Dominion Bank now owns 10,526 shares of the company’s stock valued at $610,000 after purchasing an additional 1,470 shares during the last quarter.

ALKS has been the topic of several research analyst reports. Stifel Nicolaus initiated coverage on Alkermes in a research note on Monday, August 6th. They set a “hold” rating and a $45.00 price target on the stock. Citigroup upgraded Alkermes from a “neutral” rating to a “buy” rating in a research note on Thursday, May 31st. Zacks Investment Research downgraded Alkermes from a “buy” rating to a “hold” rating in a research note on Monday, June 4th. ValuEngine upgraded Alkermes from a “strong sell” rating to a “sell” rating in a research note on Thursday, May 31st. Finally, Morgan Stanley cut Alkermes from an “equal weight” rating to an “underweight” rating and decreased their price objective for the company from $67.00 to $42.00 in a report on Thursday, June 21st. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and seven have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $55.71.

In related news, Director Floyd E. Bloom sold 20,000 shares of the company’s stock in a transaction dated Monday, July 16th. The stock was sold at an average price of $43.95, for a total value of $879,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Paul J. Mitchell sold 1,000 shares of the company’s stock in a transaction dated Tuesday, September 4th. The stock was sold at an average price of $44.58, for a total value of $44,580.00. Following the completion of the transaction, the director now directly owns 8,000 shares of the company’s stock, valued at approximately $356,640. The disclosure for this sale can be found here. Insiders sold a total of 23,000 shares of company stock valued at $1,009,120 in the last ninety days. 5.51% of the stock is currently owned by insiders.

Shares of ALKS stock opened at $42.69 on Wednesday. The company has a current ratio of 2.92, a quick ratio of 2.62 and a debt-to-equity ratio of 0.24. Alkermes Plc has a 52-week low of $38.23 and a 52-week high of $71.22.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings results on Thursday, July 26th. The company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.40. The company had revenue of $304.64 million during the quarter, compared to analysts’ expectations of $261.58 million. Alkermes had a negative return on equity of 0.29% and a negative net margin of 13.81%. Alkermes’s quarterly revenue was up 39.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.01 EPS. analysts predict that Alkermes Plc will post -0.67 EPS for the current fiscal year.

Alkermes Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) and BYDUREON BCise for the treatment of type 2 diabetes.

Recommended Story: The Role of a Fiduciary and Individual Investors

Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes Plc (NASDAQ:ALKS).

Institutional Ownership by Quarter for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.